LEVERKUSEN (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that Japanese company Bayer Yakuhin, Ltd., a subsidiary of Bayer HealthCare has received the approval from the Japanese Ministry of Health, Labour and Welfare, for usage of Eylea, or aflibercept injection in patients with diabetic macular edema - DME.
Diabetic macular edema or swelling of the macula is an eye disorder caused by leaking macular capillaries, common in diabetes patients.
Eylea is an eye injection approved for macular edema and related eye complications, developed by a collaboration of Bayer HealthCare and Regeneron.
It has previously been approved in Japan for neovascular age-related macular degeneration, macular edema secondary to central retinal vein occlusion - CRVO, and myopic choroidal neovascularization -myopic CNV, the company said.
Copyright RTT News/dpa-AFX